Jay Bradner: Gene Control Medicines: Chemical Biology & Therapeutics
In this Assay Guidance Manual Webinar from September 22, 2023, Dr. Jay Bradner discusses transcription factor ligand discovery ...
Executive Vice President of Research & Development, Amgen
Search every verified James Bradner interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. James Bradner, then president of the Novartis Institutes for Biomedical Research, delivered a keynote address at the 2021 UMass Boston–Dana-Farber/Harvard Cancer Center Annual Cancer Symposium. During the talk, he discussed the development of KRAS G12C inhibitors, noting that a "blueprint" published by a UCSF professor led to molecules that bind to the cysteine 12 residue of the G12C mutant. He described a patient who received three months of a G12C therapy from Amgen and stated that combining a G12C inhibitor with a SHP2 inhibitor showed "true synergy" in killing cancer cells. Bradner also emphasized the need for small, nimble teams to "violate the dogma of science" and advocated for diversity and inclusivity in research, saying "the science demands" it. In a 2011 TED Talk, Bradner described his lab's open-source approach to cancer research, in which they published the chemical identity of a prototype compound (JQ1) and mailed samples to 40 labs. He noted that leukemia cells treated with the compound turned into normal white blood cells and that mice with multiple myeloma responded to the drug. Bradner characterized the effort as a "social experiment" in openness and crowdsourcing, funded by the public and foundations, and stated that the molecule would be developed by a start-up called Tensha Therapeutics.
In this Assay Guidance Manual Webinar from September 22, 2023, Dr. Jay Bradner discusses transcription factor ligand discovery ...
Jay Bradner, president of Novartis Institutes for Biomedical Research, on his journey from open biology advocate to pharma leadership.
Ep93: Jay Bradner of Novartis & Andy Plump of Takeda on Mentoring Young Scientists
Jay Bradner is President of the Novartis Institutes for BioMedical Research (NIBR), the company's innovation engine. He leads ...
In the closing remarks to this year's symposium, NIBR President Jay Bradner highlights key learnings from the day and offers four ...
In opening remarks for the first NIBR Science of Therapeutics (NSofT) Symposium, NIBR President Jay Bradner welcomes attendees to a “ruthlessly scientific, atomic-level gathering of drug hunters motivated and interested in” developing antiviral therapeutics for coronaviruses – including the SARS-CoV-2 virus responsible for the global pandemic. Part of the NIBR Science of Therapeutics Symposium on Coronavirus Antivirals, June 8, 2021. Learn more: https://bit.ly/3y5dj76 ©2021 Novartis AG
The UMass Boston - DF/HCC Partnership presents its Annual Cancer Symposium featuring keynote speaker Dr. James Bradner from Novartis Institutes for Biomedical Research. To learn more about the Partnership, visit our website at www.umb.edu/u54
Part of the MacLean Center 2020-2021 Lecture Series "Ethics and the COVID-19 Pandemic: Medical, Social, and Political Issues."
The twelfth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. James Bradner of Novartis Institutes gave a talk titled "Small molecule therapeutics." For more information on the class, visit https://bit.ly/700Covid. Date: 11/24/2020 Help us make more classes like this free to the public: https://biology.mit.edu/support-biology -- Watch more videos from MIT Bio: / @mitdepartmentofbiology1187 The department is home to approximately 180 undergraduates, 200 graduate students, 200 postdoctoral researchers, and more than 60 world-reno…
James Bradner, MD, Medical Oncologist, describes what it takes to assemble the building blocks in research that lead to cures for cancer. This brief talk to donors at our Joint Visiting Committee Symposium gives a glimpse into his research in cancer chemical biology, which is helping Dana-Farber pave the way to a world without cancer.
Copyright Broad Institute, 2013. All rights reserved. In this video, Broad researcher Jay Bradner explains how high-throughput screening was used to search for potential new treatments for multiple myeloma, an incurable illness, and how Broad scientists then optimized a promising molecule. For more on screening, see this Science in Action video featuring Broad researcher Nicky Tolliday ( • Science in Action: Nicky Tolliday ). Please see Dr. Bradner's lab site (http://bradner.dfci.harvard.edu/bradn...) for more information about his work, or watch his talk (http://www.broadinstitute.org/nod…
Sign in to search the full transcript archive, filter by topic, and access every quote from James Bradner.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans